Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to�…

Although usually benign, anterior pituitary tumours occasionally exhibit aggressive
behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional�…

Pituitary neuroendocrine tumors (PitNETs) are common, with five main histological subtypes:
lactotroph, somatotroph, and thyrotroph (POU1F1/PIT1 lineage); corticotroph (TBX19/TPIT�…

Objective To describe clinical and pathological characteristics and treatment outcomes in a
large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). Design�…

Objective To collect outcome data in a large cohort of patients with aggressive pituitary
tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ)�…

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced�…

Dopamine agonists are usually very effective in the treatment of prolactinomas.
Nonetheless, a subset of individuals does not respond satisfactorily to these agents, and this�…

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to�…

Substantial advances have been made recently in the pathobiology of pituitary tumors.
Similar to many other endocrine tumors, over the last few years we have recognized the role�…

Context Pituitary carcinoma is a rare and aggressive malignancy with a poor prognosis and
few effective treatment options. Case A 35-year-old woman presented with an aggressive�…